Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed/ Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia

NCT04049383 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT04049383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04049383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed/ Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia
Lead sponsor
Medical College of Wisconsin
Phase
Phase 1
Overall status
Terminated
Start date
October 16, 2020
Completion date
September 1, 2025
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute lymphoblastic leukemia not having achieved remission, acute lymphoblastic leukemia recurrent, acute lymphoblastic leukemia with failed remission, acute lymphoblastic leukemia, in relapse, acute lymphoblastic leukemia, pediatric